FAB subtypes and cytogenetics of each patient at baseline
Patient no. . | FAB subtype . | Disease status at start of imatinib . | Cytogenetic alterations involving the PDGF-R gene locus . | Risk classification*/cytogenetic analysis . |
|---|---|---|---|---|
| 1 | M4 | 3rd relapse | Negative | Intermediate/46,XY |
| 2 | M2 | 1st relapse | Negative | Intermediate/del(12)(p) |
| 3 | ND | 2nd relapse | Negative | Poor/t(11;19)(q23;p13) |
| 4 | ND | Refractory | Negative | Poor/complex abnormalities; del(3)(q) |
| 5 | M2 | 1st relapse | Negative | Intermediate/del(20(q) |
| 6 | M2 | 1st relapse | Negative | Intermediate/45,X |
| 7 | M1 | Refractory | Negative | Intermediate/46,XY |
| 8 | M5b | Refractory | Negative | Intermediate/trisomy 21 |
| 9 | M2 | 1st relapse | Negative | Poor/complex abnormalities; -7 |
| 10 | Sec AML | Refractory | Negative | Intermediate/46,XY |
| 11 | ND | 1st relapse | Negative | Intermediate/46,XX |
| 12 | M4 | Chemonaive | Negative | Intermediate/46,XX |
| 13 | ND | 1st relapse | Negative | Intermediate/46,XX |
| 14 | M5a | Chemonaive | Negative | Intermediate/46,XX, del(20)(q) |
| 15 | M5a | 1st relapse | Negative | Poor/del(5)(q) |
| 16 | ND | 1st relapse | ND | ND |
| 17 | M0 | Refractory | Negative | Poor/-7; inv(3)(qq) |
| 18 | M5a | 1st relapse | Negative | Poor/complex abnormalities; -7 |
| 19 | M0 | 1st relapse | Negative | Poor/complex abnormalities; -7;-3 |
| 20 | ND | 1st relapse | Negative | Poor/complex abnormalities; -5 |
| 21 | ND | Chemonaive | Negative | Intermediate/46,XY |
Patient no. . | FAB subtype . | Disease status at start of imatinib . | Cytogenetic alterations involving the PDGF-R gene locus . | Risk classification*/cytogenetic analysis . |
|---|---|---|---|---|
| 1 | M4 | 3rd relapse | Negative | Intermediate/46,XY |
| 2 | M2 | 1st relapse | Negative | Intermediate/del(12)(p) |
| 3 | ND | 2nd relapse | Negative | Poor/t(11;19)(q23;p13) |
| 4 | ND | Refractory | Negative | Poor/complex abnormalities; del(3)(q) |
| 5 | M2 | 1st relapse | Negative | Intermediate/del(20(q) |
| 6 | M2 | 1st relapse | Negative | Intermediate/45,X |
| 7 | M1 | Refractory | Negative | Intermediate/46,XY |
| 8 | M5b | Refractory | Negative | Intermediate/trisomy 21 |
| 9 | M2 | 1st relapse | Negative | Poor/complex abnormalities; -7 |
| 10 | Sec AML | Refractory | Negative | Intermediate/46,XY |
| 11 | ND | 1st relapse | Negative | Intermediate/46,XX |
| 12 | M4 | Chemonaive | Negative | Intermediate/46,XX |
| 13 | ND | 1st relapse | Negative | Intermediate/46,XX |
| 14 | M5a | Chemonaive | Negative | Intermediate/46,XX, del(20)(q) |
| 15 | M5a | 1st relapse | Negative | Poor/del(5)(q) |
| 16 | ND | 1st relapse | ND | ND |
| 17 | M0 | Refractory | Negative | Poor/-7; inv(3)(qq) |
| 18 | M5a | 1st relapse | Negative | Poor/complex abnormalities; -7 |
| 19 | M0 | 1st relapse | Negative | Poor/complex abnormalities; -7;-3 |
| 20 | ND | 1st relapse | Negative | Poor/complex abnormalities; -5 |
| 21 | ND | Chemonaive | Negative | Intermediate/46,XY |
PN indicates patient number; FAB, French-American-British classification group; ND, not determined; and refractory, failure of initial therapy.
According to risk group definition of the HOVON/SAKK (Dutch-Belgian Cooperative Hemato-Oncology/Swiss Cancer study) group.50